Project Grant R16AI200951
- The National Institute of Allergy and Infectious Diseases awarded Whitehead Institute for Biomedical Research $899,850 on February 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how apicomplexan parasites recognize and invade host cells. The funded research examines the molecular mechanisms by which parasites such as Toxoplasma and Plasmodium trigger rhoptry discharge—the secretion of proteins from specialized organelles upon contact with host...
- The National Institute of Allergy and Infectious Diseases awarded William Marsh Rice University $409,024 on February 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize the structure and mechanism of Plasmodium falciparum apicoplast DNA polymerase and identify druggable allosteric sites for development of new antimalarial inhibitors. The research addresses drug-resistant malaria by targeting the apicoplast, a metabolically essential organelle...
- The National Institute of Allergy and Infectious Diseases awarded The Pennsylvania State University $247,000 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to study mechanisms of translational repression release in Plasmodium parasites during transmission from mammals to mosquito vectors. The research applies reverse genetic, transcriptomic, proteomic, and microscopy-based approaches to determine how malaria parasites control gene expression before and...
- The National Institute of Allergy and Infectious Diseases awarded New Mexico State University $146,671 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on September 3, 2026, for a project grant (R16AI201108) investigating the link between immunometabolism and epigenetics in the malaria vector mosquito Anopheles stephensi. The project employs a multi-omics approach integrating metabolomic, epigenomic, and transcriptomic data to establish mechanistic linkages between...
- The National Institute of Allergy and Infectious Diseases awarded Iowa State University $578,956 on July 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on the regulation of axoneme assembly during Plasmodium falciparum gametogenesis, a study aimed at advancing malaria vaccine development. The project, designated R01AI195769, runs through June 30, 2031, with work performed in Ames, Iowa. The research addresses the mechanisms of flagellar...
- The National Institute of Allergy and Infectious Diseases awarded $596,318 to The University of Texas Southwestern Medical Center on February 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define virulence factor functions in Salmonella enterica using minimal pathogen genomes. The research characterizes how a small network of SPI-2 type III secretion system effector proteins coordinate membrane scission of the Salmonella-containing vacuole (SCV) and...
- The National Institute of Allergy and Infectious Diseases awarded the University of South Florida $203,060 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the ecology and transmission dynamics of Plasmodium malariae in Cameroon. The research will assess the spatial distribution and seasonal trends of P. malariae in Bangolan, a lakeshore area in Cameroon's northwest region, through molecular surveillance conducted via repeated...
- The National Institute of Allergy and Infectious Diseases awarded Kansas State University $738,183 on July 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize the immunoregulatory protease network that controls melanization in Anopheles gambiae, the African malaria mosquito vector. The research identifies molecular interactions that regulate phenoloxidase activation and melanization cascade proteases, with the objective of understanding how protease...
- The National Institute of Allergy and Infectious Diseases awarded the National Science And Technology Development Agency $117,504 on September 24, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will conduct biochemical investigations of two Plasmodium falciparum folate transporters, PFFT1 and PFFT2, to characterize their function and substrate scope. The work will assess the transporters' ability to transport antifolate drugs, identify...
- The National Institute of Allergy and Infectious Diseases awarded the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. $223,728 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate Plasmodium falciparum gametocyte differentiation and adhesion mechanisms as part of Project Grant R21AI199783. The funded research addresses malaria transmission by examining the sexual stage parasites (gametocytes) responsible for...
The National Institute of Allergy and Infectious Diseases awarded Texas State University $188,124 on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on the molecular basis for Plasmodium rhoptry development. The research investigates how the aspartic protease plasmepsin IX and the glycosylphosphatidylinositol-anchored rhoptry-associated membrane antigen coordinate during rhoptry maturation in the malaria parasite. Rhoptries are specialized organelles that discharge effector proteins essential for parasite invasion of host red blood cells. The study will characterize the mechanisms governing protein compartmentalization within rhoptry structures and the proteolytic processing of rhoptry-associated membrane antigen, with the objective of developing novel therapeutic strategies against malaria infection. The project will provide training in genetic, cell biological, and biochemical techniques to undergraduate and graduate students. The award is a Project Grant with a period of performance through July 31, 2030. Work will be performed in Texas.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $188.1k | 8/17/26 |